NCT06951217View on ClinicalTrials.gov

An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

PHASE2RecruitingINTERVENTIONAL
Enrollment

340

Participants

Timeline

Start Date

April 17, 2025

Primary Completion Date

December 31, 2031

Study Completion Date

December 31, 2031

Conditions
Progressive Pulmonary FibrosisIdiopathic Pulmonary Fibrosis (IPF)
Interventions
COMBINATION_PRODUCT

AP01

AP01 will be administered open-label via the eFlow Nebulizer System

Trial Locations (11)

2145

RECRUITING

Westmead Hospital, Westmead

Unknown

RECRUITING

Royal Prince Alfred Hospital, Camperdown

RECRUITING

The Prince Charles Hospital (TPCH), Chermside

RECRUITING

Respiratory Clinical Trials PTY Ltd, Kent Town

RECRUITING

Univ of Western Australia / Institute for Respiratory Health, Nedlands

RECRUITING

John Hunter Hospital, New Lambton Heights

RECRUITING

Fakultni Thomayerove nemocnice, Praha Klanovice

RECRUITING

St Antonius Hospital, Nieuwegein

RECRUITING

Greenlane Clinical Centre, Auckland

RECRUITING

Waikato Hospital, Hamilton

RECRUITING

Leicester Biomedical Research Centre, Leicester

Sponsors

Lead Sponsor

Avalyn Pharma Inc.
All Listed Sponsors
lead

Avalyn Pharma Inc.

INDUSTRY